

●▶ **ResVita Bio**

*(FDA , Orphan Drug Designation )*

ResVita Bio receives FDA orphan drug esignation for RVB-003 to treat netherton syndrome

---

●▶ **Novartis**

*(FDA)*

Novartis receives FDA accelerated approval for VANRAFIA® to reduce proteinuria in IgA nephropathy

---

●▶ **ESTEVE**

*( Agreement )*

ESTEVE signs global license and supply agreement with Eton pharmaceuticals for INCRELEX®, excluding the USA

---

●▶ **Flagship**

*( Partnership )*

Flagship Pioneering partners with Pfizer to develop novel selective inhibitors for autoimmune diseases

---

●▶ **GRIN Therapeutics**

*( EmA, PRIME Designation )*

GRIN Therapeutics granted EMA PRIME designation for Radiprodil in GRIN-related neurodevelopmental disorder





●▶ **Accord Healthcare**

*( CHMP opinion )*

Accord Healthcare receives positive CHMP opinion for denosumab products OSVYRTI® and JUBEREQ®

---

●▶ **Amgen**

*( FDA )*

FDA approves Amgen's UPLIZNA as first and only treatment for adults with IgG4-related disease

---

●▶ **Luye Pharma**

*( Clinica data )*

Luye pharma launches ERZOFRI® in the U.S. for schizophrenia and schizoaffective disorder treatment

---

●▶ **ABL Bio + GSK**

*( Agreement )*

ABL Bio signs grabody-B brain delivery Platform licensing deal with GSK to develop neurodegenerative disease therapies

---

●▶ **Johnson & Johnson**

*( Clinica data, QIDP )*

JNJ's TREMFYA® meets primary and key secondary endpoints in active psoriatic arthritis at 24 weeks in the phase 3b APEX study

